

# Journal Pre-proof

Toxicity of diuron metabolites in human cells

Ali Mustafa Mohammed

(Conceptualization)<ce:contributor-role>Formal Analysis)

(Investigation)<ce:contributor-role>Writing- review and editing),

Marjo Huovinen (Conceptualization)<ce:contributor-role>Formal


Analysis) (Investigation)<ce:contributor-role>Writing- review and

editing), Kirsi H. Vähäkangas

(Conceptualization)<ce:contributor-role>Formal

Analysis)<ce:contributor-role>Writing- review and editing)

(Supervision)



PII: S1382-6689(20)30085-5

DOI: <https://doi.org/10.1016/j.etap.2020.103409>

Reference: ENVTOX 103409

To appear in: *Environmental Toxicology and Pharmacology*

Received Date: 7 April 2020

Revised Date: 7 May 2020

Accepted Date: 8 May 2020

Please cite this article as: Mohammed AM, Huovinen M, Vähäkangas KH, Toxicity of diuron metabolites in human cells, *Environmental Toxicology and Pharmacology* (2020), doi: <https://doi.org/10.1016/j.etap.2020.103409>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

## Toxicity of diuron metabolites in human cells.

Ali Mustafa Mohammed\*, Marjo Huovinen\*+, Kirsi H. Vähäkangas

*University of Eastern Finland, Faculty of Health Sciences, School of Pharmacy/Toxicology,  
P.O.Box 1627, 70211 Kuopio, Finland*

\*equal contribution

+Corresponding author:

Marjo Huovinen, PhD

University of Eastern Finland, Faculty of Health Sciences, School of Pharmacy

Email: marjo.huovinen@uef.fi

Phone: +358 40 355 2419

### Highlights

- Diuron metabolites were toxic in human cancer cell lines BeWo, MCF-7 and Caco-2.
- Clear toxicity by MTT assay indicates mitochondrial-mediated toxicity.
- In comparison between the cell lines, MCF-7 was the most resistant.
- Increased ROS may not explain cytotoxicity of diuron metabolites.

### Abstract

Diuron, a highly used herbicide worldwide, is metabolized into several toxic metabolites. DCA (3,4-dichloraniline), DCPU [3-(3, 4-dichlorophenyl)urea] and DCPMU [3-(3,4-dichlorophenyl)-1-methyl urea] reduced viability of human placental choriocarcinoma BeWo, human breast adenocarcinoma MCF-7 and human colon adenocarcinoma Caco-2 cells as judged by the MTT assay, where color formation is dependent on functional mitochondria in viable cells. Based on the  $IC_{50}$  values in BeWo cells the order of cytotoxicity was DCA>DCPU>diuron>DCPMU, and in Caco-2 cells DCPMU>DCPU>DCA, diuron. In MCF-7 cells, only DCPU had an  $IC_{50}$  within the range of the concentrations used. In the PI-digitonin viability assay, only the highest concentration (200  $\mu$ M) of DCPU caused a statistically

significant decrease in viability in any cell line. There was no correlation between cytotoxicity and ROS production. This indicates that diuron metabolites are toxic in cells of human origin with mitochondria as the target, but ROS not the likely mechanism.

Key words: MCF-7, BeWo, Caco-2, ROS, MTT assay

## 1. Introduction

Diuron is a herbicide being one of the most effective and highly used antifouling agents worldwide. It controls vegetation by impairing the photosynthesis related growth of unwanted weeds. Diuron is a phenylurea derivative classified as possibly carcinogenic according to the US-EPA (1997). It is highly stable and persistent, particularly in aquatic environment. Thus, exposure to diuron appears to be inevitable, which poses a threat to aquatic organisms and probably also to highly sensitive individuals, such as developing fetus. Diuron is slowly degraded in the environment by microbes or hydrolysis in water into an equally or more toxic byproduct 3,4-dichloroaniline (DCA), which in lower organisms is also a metabolite of the well-known pesticides propanil (Williams and Jacobson, 1966) and linuron (Engelhardt et al., 1971). This is the reason why there are more studies on DCA than on the other diuron metabolites.

In rats and dogs, diuron has been found to be metabolized primarily to 3-(3, 4-dichlorophenyl)urea (DCPU) followed by 3-(3,4-dichlorophenyl)-1-methyl urea (DCPMU), DCA and 3,4-dichlorophenol (Hodge et al., 1967). However, in a more recent study DCPMU was the only diuron metabolite detected in incubations with various mammalian liver microsomal preparations, with the ranking order of DCPMU formation being dog > monkey > rabbit > mouse > human > minipig > rat (Abass et al., 2007). In the only existing human study, describing analysis of diuron and its metabolites in postmortem urine and blood of one person, van Boven and coworkers (1990) found DCPMU and DCPU. Traces of DCA and 6-OH-DCPU were also detected but only in urine.

Although the toxicity of diuron and DCA have been studied *in vivo* in animals, there is no toxicity data in human *in vivo*. Furthermore, the toxicity of DCPU and DCPMU have not been studied *in vivo* in animals. *In vitro* only one study on all the three main diuron metabolites (DCPU, DCPMU, DCA) exists (Da Rocha et al., 2013), but DCA has been studied more. It is believed that diuron metabolites, mainly DCPU as the main metabolite, are responsible for the

development of urothelial cancer *in vivo* in rats (Da Rocha et al., 2013). According to a viability assay conducted in MYP3 rat urothelial cells, all diuron metabolites were cytotoxic with DCPMU being the most potent, whereas DCA was the most cytotoxic in 1T1, human urothelial cells. Similarly, microarray analysis by Da Rocha and coworkers (2013) showed that DCA alters the largest number of probe-sets in human urothelial cells. If a person is exposed to diuron, DCA is also formed, but only in minute amounts (van Boven et al., 1990).

DCA has been cytotoxic in isolated rat renal cortical cells (Rankin et al., 2008) and in hepatic and renal tissue slices (Rankin et al., 2008; Valentovic et al., 1995). DCA is also toxic *in vivo* in rats with kidney, liver, and urinary bladder as the target organs of acute toxicity (Valentovic et al., 1997). Additionally, DCA has been found hemotoxic in rats, characterized by reductions in platelet count, total number of leukocytes and the percentage of lymphocytes, as well as dose-dependent induction of methemoglobin formation (Guilhermino et al., 1998). *In vivo* toxicity studies in animals indicate that DCA is immunotoxic (Barnett et al., 1992), and nephrotoxic (Valentovic et al., 1997). In V29 Chinese hamster cells, and also in cultured human lymphocytes, DCA has induced aneuploidy (Bauchinger et al., 1989). Moreover, Zhang and Lin (2009) have described that in rats DCA alters important testicular enzymes involved in spermatogenesis indicating reproductive toxicity.

We have shown that diuron can easily cross human placenta in human placental perfusion implicating fetal exposure and fetotoxicity (Mohammed et al., 2018). Furthermore, diuron was metabolized to the toxic metabolite DCPMU in human placenta during the perfusions. This metabolite was found both in maternal and fetal circulations and traces in placental tissue after the perfusions. *In vivo*, fetus is most probably also exposed to diuron metabolites formed in maternal liver and probably in fetal liver that also has xenobiotic metabolizing capacity (for a review, see Myllynen et al., 2009). In human cells, so far, the toxicity of diuron metabolites have been studied in blood cells (Bauchinger et al., 1989; Malerba et al., 2002) and in urothelial cells (Da Rocha et al., 2013).

In the literature, human cancer cell lines differ in their sensitivity to various toxic compounds. The robustness of the cell lines differs depending on the compound studied and on the test system applied (Coleman et al., 2007; Xu et al., 2016; El-Zahabi et al., 2019; Silva et al., 2019). In our previous study using human cancer cell lines, diuron decreased viability of human placental choriocarcinoma BeWo cells, which are placental trophoblastic cells representing cells of fetal origin, but did not affect viability of human breast adenocarcinoma cells (MCF-

7) (Huovinen et al., 2015). Increased production of ROS by diuron was observed in both types of cells which could explain part of the toxicity of diuron. In this study, we used the same human cell lines (MCF-7 and BeWo), as well as human colon adenocarcinoma cells Caco-2 in order to gain more insight into potential human toxicity of the main diuron metabolites.

## 2. Materials and methods

### 2.1. Cell culture and chemical treatments

Human placental choriocarcinoma BeWo and human breast adenocarcinoma MCF-7 cells were cultured as described earlier (Huovinen et al., 2015). Human colon adenocarcinoma cells (Caco-2) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, BioWhittaker, Belgium) containing 4.5 g/l glucose and supplemented with 9% fetal bovine serum, 1 mM sodium pyruvate, 1 x non-essential amino acids, 2 mM L-glutamine, and a combination of penicillin and streptomycin. The cells (Caco-2, BeWo and MCF-7) were seeded on 48 well-plates at a density of 30 000-40 000 cells/ml and treated with the concentrations of 25-200  $\mu$ M of DCPMU, DCA or DCPU for 48 hours. Caco-2 cells were also treated with 50, 100, 150 or 200  $\mu$ M of diuron. Control cells were treated with equivalent volumes of DMSO (0.1%, Sigma-Aldrich, USA).

### 2.2. Cell Viability

#### 2.2.1. MTT assay

The experiments were carried out on 48-well plates as described earlier (Huovinen et al., 2015). MTT assay is based on the conversion of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] into a colored compound known as formazan by functioning mitochondria in viable cells. Decrease of absorbance indicates cytotoxicity. Four to five individual experiments (plates) were carried out for each compound with four replicates per concentration in every experiment. Viability was expressed as percent from control.

#### 2.2.2. Propidium Iodide-digitonin assay

Analyses were carried out on 48-well plates according to the method of Sarafian et al. (1994), as described previously (Huovinen et al., 2011; Loikkanen et al., 2003). Briefly, at the end of the treatment with diuron or its metabolites, propidium iodide (PI) was added into the cell

cultures, incubated for 20 minutes at room temperature (RT), and the fluorescence was analyzed. If the cell membrane is damaged, PI will bind to the nucleic acids and the fluorescence of PI is increased by approximately 20-30-fold. In order to count the total number of cells, the cultures were additionally treated with digitonin (for 20 minutes at RT), which causes damage to the cell membranes allowing PI to enter all the cells. After incubation, the maximum fluorescence was analyzed. Viability is expressed as percent fluorescence related to the maximum fluorescence of the corresponding sample, and the relative cell number is expressed as percentage from control values (Huovinen et al., 2011). Four to five independent experiments (plates) were carried out for each concentration of the compounds with four replicates on each plate.

### 2.2.3. *Reactive oxygen species.*

The production of reactive oxygen species (ROS) was analyzed on 48-well plates using the substrate 2',7'-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA) as described previously (Tampio et al., 2009). Three to seven individual experiments (plates) were carried out for each compound with four replicates per concentration in every experiment. Production of ROS was expressed as percent from control.

### 2.2.4. *Liquid chromatography- mass spectrometry*

Cell cultures were analyzed for diuron and its metabolites, DCPMU, DCPU and DCA, using Agilent 6410 Triple Quadruple LC-MS (G6410A) (Agilent Technologies, USA). The method is described in detail by Mohammed et al. (2018).

### 2.3. *Calculations and statistical analysis.*

The 50% inhibitory concentration (IC<sub>50</sub>)-values were calculated from MTT data using non-linear regression analysis. Also, IC<sub>50</sub> values of diuron cytotoxicity in BeWo and MCF-7 were calculated from our earlier MTT data (Huovinen et al., 2015) in order to compare the toxicity of diuron and its metabolites.

One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test were used for statistical calculations in all comparisons.  $P < 0.05$  was considered as statistically significant. Results of viability assays, relative cell numbers and ROS were expressed as a mean  $\pm$  standard deviation. Graph-Pad Prism 5.05 was used to compute the IC<sub>50</sub>-values and for statistics.

### 3. Results

#### 3.1. Metabolism of diuron

CaCo-2 and MCF-7 cells were treated with up to 200 $\mu$ M of diuron for 48 hours. DCPMU was the only metabolite formed after exposure to  $\geq 100\mu$ M in both types of cells. No DCPU was found. As to DCA, a peak with a similar retention time to that of the standard was obtained, but the peak did not identically match the molecular ion of DCA standard and thus it could not be identified with certainty.

#### 3.2 Toxicity of diuron metabolites in human cells

DCPMU and DCPU reduced the viability of cells of all the cell lines as judged by the MTT assay (Fig 1). DCA reduced the viability of BeWo and Caco-2 cells but not MCF-7 cells. According to  $IC_{50}$ -values in BeWo cells, the order of cytotoxicity was DCA>DCPU>diuron>DCPMU, and in Caco-2 cells DCPMU, DCPU>DCA, diuron. In MCF-7 cells only DCPU had an  $IC_{50}$  within the range of the concentrations used (Table 1).

With the other viability assay, PI-digtonin, only DCPU showed a statistically significant decrease in viability in all the three cell lines (Table 2; Fig S1). By the PI-digtonin assay, DCPMU decreased cell viability statistically significantly only in Caco-2 cells.  $IC_{50}$  values could not be calculated accurately from this data, because the computed  $IC_{50}$  values were higher than the highest concentration used.

Relative cell number, which indicates a decrease in viability, and/or inhibition of proliferation, decreased statistically significantly only with DCPMU in Caco-2 cells and with DCA in BeWo cells (Table 2; Fig S2). ROS increased statistically significantly in all the cell lines only by DCA (Fig. 2). DCPMU increased ROS in BeWo and MCF-7 cells, and DCPU only in BeWo cells (Fig 2).

#### 3.3 Sensitivity of the cell lines to diuron metabolites

There were differences in the responses to the diuron metabolites between the cell-lines depending on the analysis carried out. In MTT test indicating damage to mitochondrial function, BeWo cells were the most sensitive, so that DCA decreased the viability already at the concentration of 25  $\mu$ M, and DCPU at 50  $\mu$ M (Fig. 1). Caco-2 cells were the most sensitive



to DCPMU, viability decreasing at the concentrations of 50  $\mu\text{M}$  or higher (Fig 1). In MTT assay MCF-7 cells were the most resistant to the cytotoxicity by diuron metabolites.

In the other assay for viability, the PI-digitonin assay, which indicates cell membrane damage, there were no big differences between the cell lines and the cells were quite resistant to all the used diuron metabolites (Table 2; Fig S1). As to the relative cell number, only BeWo and CaCo-2 were somewhat sensitive to the decrease (Table 1; Fig. S2). In Caco-2 cells the concentrations above 100  $\mu\text{M}$  of DCPMU, and in BeWo cells 200  $\mu\text{M}$  decreased the number of cells statistically significantly.

ROS production was most prominent in MCF-7 cells, where DCA induced a statistically significant increase in ROS already at 50  $\mu\text{M}$  concentration (Fig 2). However, as to the other cell lines, statistically significant increases were noted only by the highest (200  $\mu\text{M}$ ) concentration. BeWo cells were the only ones where all three metabolites increased ROS statistically significantly.

#### *3.4 Comparison of diuron toxicity in cell lines*

We have earlier studied toxicity of diuron in BeWo and MCF-7 cells (Huovinen et al., 2015). To complete the picture, toxicity of diuron in Caco-2 cells was also studied.  $\text{IC}_{50}$ -values were calculated from current MTT data for Caco-2 cells, and earlier MTT data for BeWo and MCF-7 cells from Huovinen et al. (2015) in order to compare the toxicity of diuron among the cell lines and to compare diuron with its metabolites. The  $\text{IC}_{50}$  of diuron in BeWo cells was the only one within the range of the concentrations used (Table 1).

Viability of Caco-2 cells by MTT assay and the relative cell number decreased statistically significantly (Fig 3A and 3D). However, no decrease in viability by PI-digitonin (Fig 3C) or increase in ROS production (Fig 3D) was noticed.

## **4. Discussion**

This study demonstrates toxicity of diuron metabolites in three human cancer cell lines. This is in line with the study by Da Rocha and coworkers (2013), the only earlier study on cytotoxicity of diuron metabolites in cells of human origin. They showed cytotoxicity by diuron metabolites in human urothelial 1T1 cells derived from normal human ureter epithelium and immortalized by transfection of the HPV-16 E6 and E7 genes (Tamatani et al., 1999). Our

study and that by Rocha and coworkers provide basic toxicity data for further molecular studies to pursue mechanisms of toxicity of diuron and its metabolites.

We found differences in the toxicity among the three metabolites in the used cell lines. Interestingly, the order of toxicity of diuron metabolites based on  $IC_{50}$  values in BeWo cells was similar to that observed in human urothelial cells; DCA>DCPU>DCPMU (Da Rocha et al., 2013). The  $IC_{50}$  value of DCA (73  $\mu$ M) in BeWo cells was similar to that seen in human urothelial cells (72  $\mu$ M). Toxicity of DCA to human cells is in line with a study in mice which showed that tetrachloroazobenzene, structurally related to aromatic amines and DCA, induces urethral carcinoma (Singh et al., 2010). It is known that exposure to aromatic amines is associated with bladder cancer in workers in chemical industry (Ferris et al., 2013). In Caco-2 cells, on the other hand, the order of toxicity was similar to that seen in rat urothelial cells with DCPMU and DCPU being more cytotoxic than DCA (Da Rocha et al., 2013). Our study is the first comparative study of toxicity between diuron and its metabolites in more than one human cell line. We show here that in all the three used cell lines, at least some of the diuron metabolites were more toxic than diuron. Overall, according to the  $IC_{50}$  values, BeWo cells were the most sensitive to both diuron and its metabolites. The most resistant to diuron and its metabolites were the MCF-7 cells where DCPU was the only metabolite with an  $IC_{50}$  value below the highest tested concentration.

Cytotoxicity in MTT assay, shown in our study by all diuron metabolites is indicative of mitochondrial-mediated toxicity, because the assay is based on the enzymes in functional mitochondria. We have found similar cytotoxicity earlier by diuron (Huovinen et al. 2015). Our results are also in line with earlier animal studies showing disturbance of mitochondrial functions by diuron. In rat hepatocytes, Owen and Halestrap (1993) have shown that diuron inhibits oxidative phosphorylation. In their study diuron inhibited gluconeogenesis and reduced mitochondrial ATP/ADP ratio, with a positive correlation between them (Owen and Halestrap, 1993). Likewise, in a recent *in vitro* study using isolated rat liver mitochondria, diuron inhibited cellular respiration and mitochondrial membrane bound enzyme activities (da Silva Simoes et al., 2017). In the same study, diuron reduced oxygen uptake, pyruvate production and cellular ATP content in perfused rat liver. A lack of clear toxicity by PI-digtonin assay reflecting cell membrane integrity indicates less toxicity to the cell membrane.

ROS have been hypothesized as a possible mechanism of diuron toxicity (Huovinen et al., 2015; Kao et al., 2019). This is supported by a diuron-induced, dose-dependent increase of

ROS production in human immortalized liver HepG2 cells (Kao et al., 2019). In our study, increased ROS production was seen by all diuron metabolites in at least some of the cell lines used, with most prominent ROS production in MCF-7 cells. Because MCF-7 cells were more resistant to the toxicity of the metabolites, this may reflect better condition of the MCF-7 cells after the treatment. In gene expression analysis Da Rocha and coworkers (2013) found the signaling pathways of oxidative stress response to be among the pathways induced by all three diuron metabolites (DCA, DCPU, DCPMU) in rat urothelial cells, but in human urothelial cells only by DCA and DCPU. This all is in line with the studies in lower animals where ROS production has been found as a potential mechanism of toxicity of diuron and its metabolites (Behrens et al., 2016).

However, in our study there was no correlation between the cytotoxicity and ROS production. This is in line with our earlier results showing that ROS production was not as evident in BeWo cells treated with diuron as in MCF-7 cells, more resistant to cytotoxicity by diuron (Huovinen et al., 2015). Among the diuron metabolites, DCPU was the only one altering the gene expression pathways involved in oxidative stress in urothelial cells (Da Rocha et al. 2013). Furthermore, Kao and coworkers (2019) have shown that pretreatment of HepG2 cells with N-acetylcysteine, an antioxidant, did not protect the cells from the cytotoxic effects of diuron suggesting that induction of oxidative stress is probably not the major mechanism of diuron cytotoxicity in the cells. Thus, based both on our results and those by Kao and coworkers (2019) it remains unlikely that increased production of ROS is a major mechanism of cytotoxicity by diuron and its metabolites in human cells.

Of the used cell lines, MCF-7 and BeWo cells were earlier studied for diuron toxicity (Huovinen et al., 2015). However, Caco-2 cells have not been studied for diuron toxicity or metabolism before. In all these cell lines diuron was metabolized into DCPMU (this study, Mohammed et al., 2018). Similarly to MCF-7 and BeWo cells, diuron was cytotoxic in Caco-2 cells analyzed by MTT-test. Also, our findings agree with those from the recent *in vitro* study using human HepG2 cells, in which diuron was cytotoxic in MTT assay (Kao et al., 2019). In our earlier study MCF-7 cells were more resistant to diuron toxicity than the BeWo cells (Huovinen et al., 2015). Similarly, Xu et al. (2016) found that MCF-7 cells were more resistant to triazolo-tetrazine derivatives than BeWo cells. MCF-7 cells seem to be more resistant to diuron also in comparison with Caco-2 cells. This is supported by an earlier study where the cytotoxicity with three hexadione isomers were analyzed (Coleman et al., 2007). On the other

hand, there are studies where MCF-7 cells have been more sensitive to e.g. doxorubicin (El-Zahabi et al., 2019) or epigallocatechin gallate (Silva et al., 2019) compared to Caco-2 cells.

In conclusion, our data confirm that diuron metabolites are toxic in cells of human origin. The degree of toxicity varies among the metabolites. Based on this and our earlier study (Huovinen et al., 2015) there are differences in the sensitivity of the cell lines to the toxicity by diuron and its metabolites, MCF-7 being more resistant than Caco-2 or BeWo. Mitochondrial toxicity is probably one of the major mechanisms behind the cytotoxicity. ROS production varied between the cell lines and metabolites, with no clear relation to cytotoxicity in MTT assay indicating that increase of ROS is not the mechanism of cytotoxicity.

### **CRedit authorship contribution statement**

Ali Mohammed, Marjo Huovinen, Kirsi Vähäkangas: Conceptualization, formal analysis

Ali Mohammed, Marjo Huovinen: Investigation

Ali Mohammed, Marjo Huovinen, Kirsi Vähäkangas: Writing, review and editing

Kirsi Vähäkangas: Supervision

### **Declaration of interests**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### **Acknowledgements**

The authors thank Ms. Virpi Koponen and Ms. Pirjo Hänninen for their skillful technical assistance. Mr. Frederick Ekuban, MSc, Ms. Ingrid Hagberg, MSc and Ms. Momena Raiyan, BSc are acknowledged for their contribution to the laboratory experiments. This work was financially supported by the School of Pharmacy and a fellowship to AM from the Doctoral Programme in Drug Research, University of Eastern Finland. Travel grants to AM from the Finnish Pharmacological Society and the Finnish Pharmaceutical Society are also gratefully acknowledged.

## References

- Abass, K., Reponen, P., Turpeinen, M., Jalonen, J., and Pelkonen, O. (2007). Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. *Drug Metab. Dispos.* 35, 1634-1641.
- Barnett, J.B., Gandy, J., Wilbourn, D., and Theus, S.A. (1992). Comparison of the immunotoxicity of propanil and its metabolite, 3,4-dichloroaniline, in C57Bl/6 mice. *Fundam. Appl. Toxicol.* 18, 628-631.
- Bauchinger, M., Kulka, U., and Schmid, E. (1989). Cytogenetic effects of 3,4-dichloroaniline in human lymphocytes and V79 Chinese hamster cells. *Mutat. Res.* 226, 197-202.
- Behrens, D., Rouxel, J., Burgeot, T., and Akcha, F. (2016). Comparative embryotoxicity and genotoxicity of the herbicide diuron and its metabolites in early life stages of *Crassostrea gigas*: Implication of reactive oxygen species production. *Aquat. Toxicol.* 175, 249-259.
- Coleman, M.D., Zilz, T.R., Griffiths, H.R., Woehrling, E.K. (2007). A comparison of the apoptotic and cytotoxic effects of hexanedione derivatives on human non-neuronal lines and the neuroblastoma line SH-SY5Y. *Basic Clin Pharmacol Toxicol.* 102, 25-9.
- Da Rocha, M.S., Arnold, L.L., Dodmane, P.R., Pennington, K.L., Qiu, F., De Camargo, J.L., and Cohen, S.M. (2013). Diuron metabolites and urothelial cytotoxicity: in vivo, in vitro and molecular approaches. *Toxicology* 314, 238-246.
- da Silva Simoes, M., Bracht, L., Parizotto, A.V., Comar, J.F., Peralta, R.M., and Bracht, A. (2017). The metabolic effects of diuron in the rat liver. *Environ. Toxicol. Pharmacol.* 54, 53-61.
- El-Zahabi, H.S.A., Khalifa, M.M.A., Gado, Y.M.H., Farrag, A.M., Elaasser, M.M., Safwat, N.A., AbdelRaouf, R.R., Arafa, R.K. (2019). New thiobarbituric acid scaffold-based small molecules: Synthesis, cytotoxicity, 2D-QSAR, pharmacophore modelling and in-silico ADME screening. *Eur J Pharm Sci.* 130:124-136.
- Engelhardt, G., Wallnöfer, P.R., Plapp, R. (1971). Degradation of linuron and some other herbicides and fungicides by a linuron-inducible enzyme obtained from *Bacillus sphaericus*. *Appl Microbiol.* 22, 284-288.
- Felício, AA., Freitas, JS., Scarin, JB., de Souza Ondeí, L., Teresa, FB., Schlenk, D., de Almeida, EA. (2018). Isolated and mixed effects of diuron and its metabolites on

biotransformation enzymes and oxidative stress response of Nile tilapia (*Oreochromis niloticus*). *Excotoxicol Environ Saf.* 149, 248-256.

Ferrís, J., Garcia, J., Berbel, O., Ortega, J.A. (2013). Constitutional and occupational risk factors associated with bladder cancer. *Actas Urol Esp.* 37, 513-22.

Guilhermino, L., Soares, A.M., Carvalho, A.P., and Lopes, M.C. (1998). Acute effects of 3,4-dichloroaniline on blood of male Wistar rats. *Chemosphere* 37, 619-632.

Hodge, H.C., Downs, W.L., Panner, B.S., Smith, D.W., and Maynard, E.A. (1967). Oral toxicity and metabolism of diuron (N-(3,4-dichlorophenyl)-N',N'-dimethylurea) in rats and dogs. *Food Cosmet. Toxicol.* 5, 513-531.

Huovinen, M., Loikkanen, J., Myllynen, P., and Vahakangas, K.H. (2011). Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis. *Toxicol. in Vitro.* 25, 1007-1017.

Huovinen, M., Loikkanen, J., Naarala, J., and Vahakangas, K. (2015). Toxicity of diuron in human cancer cells. *Toxicol. in Vitro.* 29, 1577-1586.

Kao, C.M., Ou, W.J., Lin, H.D., Eva, A.W., Wang, T.L., and Chen, S.C. (2019). Toxicity of diuron in HepG2 cells and zebrafish embryos. *Ecotoxicol. Environ. Saf.* 172, 432-438.

Loikkanen, J., Chvalova, K., Naarala, J., Vahakangas, K.H., and Savolainen, K.M. (2003). Pb<sup>2+</sup>-induced toxicity is associated with p53-independent apoptosis and enhanced by glutamate in GT1-7 neurons. *Toxicol. Lett.* 144, 235-246.

Malerba, I., Castoldi, A.F., Parent-Massin, D., and Gribaldo, L. (2002). In vitro myelotoxicity of propanil and 3,4-dichloroaniline on murine and human CFU-E/BFU-E progenitors. *Toxicol. Sci.* 69, 433-438.

Mohammed, A.M., Karttunen, V., Huuskonen, P., Huovinen, M., Auriola, S., and Vahakangas, K. (2018). Transplacental transfer and metabolism of diuron in human placenta. *Toxicol. Lett.* 295, 307-313.

Myllynen, P., Immonen, E., Kumm, M., and Vahakangas, K. (2009). Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. *Expert Opin. Drug Metab. Toxicol.* 5, 1483-1499.

Owen, M.R., and Halestrap, A.P. (1993). The mechanisms by which mild respiratory chain inhibitors inhibit hepatic gluconeogenesis. *Biochim. Biophys. Acta* 1142, 11-22.

Rankin, G.O., Racine, C., Sweeney, A., Kraynie, A., Anestis, D.K., and Barnett, J.B. (2008). In vitro nephrotoxicity induced by propanil. *Environ. Toxicol.* 23, 435-442.

Sarafian, T.A., Vartavarian, L., Kane, D.J., Bredesen, D.E., and Verity, M.A. (1994). bcl-2 expression decreases methyl mercury-induced free-radical generation and cell killing in a neural cell line. - PubMed - NCBI.74, 149-155.

Silva, A.M., Martins-Gomes, C., Fangueiro, J.F., Andreani, T., Souto, E.B. (2019). Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles against different cell lines. *Pharm Dev Technol.* 24, 1243-1249.

Singh, B.P., Nyska, A., Kissling, G.E., Lieuallen, W., Johansson, S.L., Malarkey, D.E., Hooth, M.J. (2010). Urethral carcinoma and hyperplasia in male and female B6C3F1 mice treated with 3,3',4,4'- Tetrachloroazobenzene (TCAB). *Toxicol Pathol* 38, 372-381.

Tamatani, T., Hattori, K., Nakashiro, K., Hayashi, Y., Wu, S., Klumpp, D., Reddy, J.K., and Oyasu, R. (1999). Neoplastic conversion of human urothelial cells in vitro by overexpression of H<sub>2</sub>O<sub>2</sub>-generating peroxisomal fatty acyl CoA oxidase. *Int. J. Oncol.* 15, 743-749.

Tampio, M., Markkanen, P., Puttonen, K.A., Hagelberg, E., Heikkinen, H., Huhtinen, K., Loikkanen, J., Hirvonen, M.R., and Vahakangas, K.H. (2009). Induction of PUMA-alpha and down-regulation of PUMA-beta expression is associated with benzo(a)pyrene-induced apoptosis in MCF-7 cells. *Toxicol. Lett.* 188, 214-222.

US Environmental Protection Agency, (USEPA), 1997. Carcinogenicity Peer Review of Diuron. Office of Prevention, Pesticides and Toxic Substances. Memorandum from Linda Taylor and Esther Rinde to Phillip Errico and Larry Schnaubelt. Chemicals Evaluated for Carcinogenic Potential, Washington, DC.

Valentovic, M.A., Ball, J.G., Anestis, D.K., and Rankin, G.O. (1995). Comparison of the in vitro toxicity of dichloroaniline structural isomers. *Toxicol. in Vitro.* 9, 75-81.

Valentovic, M.A., Yahia, T., Ball, J.G., Hong, S.K., Brown, P.I., and Rankin, G.O. (1997). 3,4-Dichloroaniline acute toxicity in male Fischer 344 rats. *Toxicology* 124, 125-134.

Van Boven, M., Laruelle, L., and Daenens, P. (1990). HPLC analysis of diuron and metabolites in blood and urine. *J. Anal. Toxicol.* 14, 231-234.

Williams, C.H., Jacobson, K.H. (1966). An acylamidase in mammalian liver hydrolyzing the herbicide 3,4-dichloropropionanilide. *Toxicol Appl Pharmacol.* 9, 495-500.

Xu, F., Yang, Z.Z., Jiang, J.R., Pan, W.G., Yang, X.L., Wu, J.Y., Zhu, Y., Wang, J., Shou, Q.Y., Wu, H.G. (2016). Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives. *Bioorg Med Chem Lett.* 26, 3042-3047.

Zhang, B., and Lin, S. (2009). Effects of 3,4-dichloroaniline on testicle enzymes as biological markers in rats. *Biomed. Environ. Sci.* 22, 40-43.










Journal Pre-proof




## BeWo cells


## Caco-2 cells

## MCF-7 cells




**Fig 1.** Cell viability, analyzed by MTT assay, of human placental choriocarcinoma BeWo cells (left column), human colon adenocarcinoma Caco-2 cells (middle column) and human breast adenocarcinoma MCF-7 cells (right column) treated with 25-200  $\mu$ M of 3-(3,4-dichlorophenyl)-1-methyl urea (DCPMU), 3-(3, 4-dichlorophenyl)urea (DCPU) or 3,4-dichloroaniline (DCA) for 48 h. The columns represent the mean  $\pm$  SD of relative values from 4-5 individual experiments (plates; n = 4 or 5 as indicated in the figure), each a mean of four replicates on the same 48-well plate; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.





**Fig. 2.** Production of reactive oxygen species (ROS) in human placental choriocarcinoma Bewo cells (left column), human colon adenocarcinoma Caco-2 cells (middle column) and human breast adenocarcinoma MCF-7 cells (right column) after treatment with 3-(3,4-dichlorophenyl)-1-methyl urea (DCPMU), 3-(3, 4-dichlorophenyl)urea (DCPU) or 3,4-dichloroaniline (DCA) for 48 h. The columns represent a mean  $\pm$  SD of relative values from 3-7 individual experiments (plates; n= 3-7 as indicated in the figure) each a mean of four replicates on the same 48-well plate. \* $p < 0.05$ , \*\*\* $p < 0.001$ .



**Fig. 3.** Toxicity of diuron in human colon adenocarcinoma Caco-2 cells. Cell viability using MTT-assay (A) or Propidium iodide (PI)-digitonin-assay (C), production of reactive oxygen species (ROS) (B) and relative cell number (D) in cells treated with the indicated concentrations of diuron for 48 h. The values are mean  $\pm$  SD from 4-5 individual experiments (plates; n= 4-5 as indicated in the figure) each a mean of four replicates on the same 48-well plate. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

Table 1. The 50% inhibitory concentration (IC<sub>50</sub>;  $\mu$ M) of diuron metabolites in human cancer cell lines y at 48 hours after treatment as analyzed by MTT assay

Metabolite	IC <sub>50</sub>		
	Bewo	Caco-2	MCF-7
<b>DCPMU</b>	188	158	>200
<b>DCPU</b>	89	152	167
<b>DCA</b>	73	>200	>200
<b>Diuron</b>	152	>200	ND

DCPMU= 3-(3,4-dichlorophenyl)-1-methyl urea; DCPU= 3-(3, 4-dichlorophenyl)urea; DCA= 3,4-dichloroaniline. ND= not determined (no difference in viability between control and treated groups).

Table 2. Concentrations of diuron metabolites inducing a statistically significant reduction of viability and/or relative cell number in human cancer cell lines as analyzed by PI-digitonin assay . Concentrations used were 25, 50, 100 or 200  $\mu$ M.

Metabolite	Viability			Relative cell number		
	Bewo	Caco-2	MCF-7	Bewo	Caco-2	MCF-7
<b>DCPMU</b>	NE	200	NE	NE	100 & 200	NE
<b>DCPU</b>	200	200	200	NE	NE	NE
<b>DCA</b>	NE	NE	NE	200	NE	NE

DCPMU= 3-(3,4-dichlorophenyl)-1-methyl urea; DCPU= 3-(3, 4-dichlorophenyl)urea; DCA= 3,4-dichloroaniline. BeWo= human placental choriocarcinoma cells; Caco-2= human colon adenocarcinoma; MCF-7= human breast adenocarcinoma; NE= no effect;